Media headlines about CVS Health (NYSE:CVS) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CVS Health earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the pharmacy operator an impact score of 46.1065862073712 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- Stockholders Approve CVS Health’s Acquisition of Aetna – Wall Street Journal (wsj.com)
- CVS Health Stockholders Approve Aetna Acquisition (finance.yahoo.com)
- CVS, Aetna shareholders approve drugstore's acquisition of health insurer (finance.yahoo.com)
- CVS shareholders approve Aetna acquisition (finance.yahoo.com)
- The Midday Rundown: March 13, 2018 (finance.yahoo.com)
A number of research firms recently commented on CVS. Morgan Stanley raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price on the stock in a research report on Friday, January 5th. Needham & Company LLC increased their target price on shares of CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. SunTrust Banks increased their target price on shares of CVS Health to $90.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Leerink Swann set a $85.00 target price on shares of CVS Health and gave the company a “buy” rating in a research report on Friday, February 9th. Finally, Mizuho set a $95.00 target price on shares of CVS Health and gave the company a “buy” rating in a research report on Wednesday, January 24th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. CVS Health currently has an average rating of “Buy” and an average target price of $87.03.
CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The company had revenue of $48.39 billion for the quarter, compared to the consensus estimate of $47.54 billion. During the same period last year, the firm posted $1.71 EPS. CVS Health’s revenue for the quarter was up 5.3% on a year-over-year basis. sell-side analysts anticipate that CVS Health will post 6.37 earnings per share for the current year.
In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Helena Foulkes sold 19,965 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares in the company, valued at $4,622,714.88. The disclosure for this sale can be found here. Company insiders own 0.61% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect CVS Health (CVS) Stock Price” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://baseballnewssource.com/2018/03/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cvs-health-cvs-stock-price/2025553.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.